Is Gilead About to Crush Pharmacyclics Stock?

Gilead (GILD) won approval for Zydelig this week as a treatment for chronic lymphocytic leukemia, but that doesn't mean that Johnson & Johnson (JNJ) and Pharmacyclics' Imbruvica is heading for the dustbin.

Jul 23, 2014 at 6:08PM

Pharmacyclics' (NASDAQ:PCYC) and Johnson & Johnson's (NYSE:JNJ) Imbruvica may be one loser following the FDA's approval of Gilead's (NASDAQ:GILD) Zydelig, or so the story went.

However, before investors begin abandoning Pharmacyclics shares thinking that Zydelig will regulate Imbruvica to the back-burner in chronic lymphocytic leukemia, or CLL, they should recognize that Imbruvica may do very well on its own despite the threat.


Source: Pharmacyclics

Treating blood cancer
CLL is a white blood cancer that starts in the bone marrow and can spread over time to other parts of the body. There are two forms of CLL, one which develops slowly and one that develops quickly.

Overall, there are about 15,700 new cases of CLL diagnosed annually in the U.S. and roughly 4,600 people die from the disease every year.

The prevalence of CLL is likely to grow over the coming years given that 10,000 baby boomers turn 65 every day and the average age of diagnosis for CLL is age 72.


Source: Pharmacyclics

Imbruvica gets the nod
Hopes have run high for Imbruvica following its approval in mantle cell leukemia last November. The FDA followed up with an approval in CLL in February following a mid stage study showing that half of treated CLL patients saw their tumors shrink.

The recent approvals, combined with potential future label expansions, have market watchers projecting that Imbruvica's peak sales could total more than $6 billion.

Imbruvica will need to differentiate itself against long standing CLL treatments including Roche's Rituxan, Gazyva, a CLL drug that notched the FDA's green-light last November, and Zydelig to hit those lofty targets.

Zydelig wins over regulators
Gilead's Zydelig notched FDA approval this week after demonstrating in phase 3 studies that patients receiving Zydelig alongside Rituxan enjoyed far better progression free survival than those receiving Rituxan alone.

In a study of 220 CLL patients, patients receiving Zydelig and Rituxan didn't see their disease progress for 10.7 months, while those in the control group saw their disease progress after just 5.5 months.

That's an imperssive showing, but before investors extrapolate that to mean it will displace Imbruvica they need to keep a few things in mind.

Black box warning and stiffer pricing
While Imbruvica doesn't carry a black box warning, Zydelig does. The warning includes risk of severe liver toxicity, diarrhea, and lung inflammation, among other risks. The drug is also being approved with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure that doctors and patients fully understand the drug's risk.

Additionally, while Gilead will charge roughly $7,200 monthly for Zydelig, which is lower than Imbruvica's $8,200, the total cost of using Zydelig alongside Rituxan (which is how Zydelig is approved) brings the treatment cost to around $12,000, or nearly $4,000 more than Imbruvica.

Expanding label
Imbruvica is approved as a second line treatment for CLL patients whose disease has progressed, but it could see the FDA expand its use both to previously untreated patients and in combination with other therapies.

In April, Pharmacyclics filed a supplemental new drug application showing that Imbruvica outperformed GlaxoSmithKline's Arzerra in patients that had previously had at least one other prior treatment.That trial was halted early after interim analysis determined that Imbruvica patients had significantly better progression free survival and overall survival than Arzerra patients.

In another trial, Imbruvica demonstrated significant benefit in pre-treated patients when use alongside Arzerra. In three groups treated with various combinations of Imbruvica and Arzerra, progression free survival after a year was 89%, 85%, and 75%, respectively. Those studies could clear the way for Imbruvica being used both before and in combination with Arzerra, which had $20 million in sales during the second quarter.

But those aren't the only trials under way for Imbruvica. Pharmacyclics and Johnson are also studying Imbruvica as an adjunct to Rituxan too. A phase 3 study comparing the combination versus Rituxan alone in previously untreated patients got under way in December and if that trial goes well it could conceivably trump Zydelig's advantage as an adjunctive to Rituxan someday.

Fool-worthy final thoughts
When it comes to cancer drugs, investors need to take their time before coming to conclusions. Cancer is notoriously tough to treat and patients who relapse often migrate from therapy to therapy. Given that backdrop, until Imbruvica shows that it can't improve disease progression, investors should be hesitant to exit shares. 

Leaked: This coming blockbuster will make Gilead and Pharmacyclics jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers